Neuromuscular Complications of Statins

Physical Medicine and Rehabilitation Clinics of North America

Volumn 19, Issue 1, 2008, Pages 47-59

  Ahn, Sung C ^a,b  

^a Loyola University ^*  (United States)

^b LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CLARITHROMYCIN; CORTICOSTEROID; CYCLOSPORIN A; DILTIAZEM; ERYTHROMYCIN; FENOFIBRATE; FLUCONAZOLE; FLUINDOSTATIN; FLUOXETINE; FLUVOXAMINE; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; KETOCONAZOLE; MEVINOLIN; MIBEFRADIL; MIDAZOLAM; NEFAZODONE; PLACEBO; RITONAVIR; ROSUVASTATIN; SERTRALINE; SIMVASTATIN; TACROLIMUS; TELITHROMYCIN; UBIQUINONE; UNINDEXED DRUG; VENLAFAXINE; VERAPAMIL;

AMNESIA; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROL GROUP; DRUG MECHANISM; DRUG WITHDRAWAL; DYSPNEA; ELECTROMYOGRAPHY; FATIGUE; HUMAN; MORTALITY; MYALGIA; MYOPATHY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

ELECTROMYOGRAPHY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; MUSCULAR DISEASES; NEUROMUSCULAR DISEASES; RHABDOMYOLYSIS; RISK FACTORS;

EID: 38049049626     PISSN: 10479651     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pmr.2007.10.002     Document Type: Review

References (48)

1. Ballantyne C.M., Corsini A., Davidson M.H., et al. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med 163 (2003) 553
2. Lewis S.J., Moye L.A., Sacks F.M., et al. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial. Ann Intern Med 129 (1998) 681
3. Sacks F.M. High-intensity statin treatment for coronary heart disease. JAMA 291 (2004) 1132
4. Pasternak R. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. [see comment]. Stroke 33 (2002) 2337
5. Graham D.J., Staffa J.A., Shatin D., et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. [see comment]. JAMA 292 (2004) 2585
6. Thompson P.D., Clarkson P., and Karas R.H. Statin-associated myopathy. JAMA 289 (2003) 1681
7. Law M., and Rudnicka A.R. Statin safety: a systematic review. Am J Cardiol 97 (2006) 52C
8. Jones P.H., and Davidson M.H. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol 95 (2005) 120
9. Bellosta S., Paoletti R., and Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 109 (2004) III50
10. Rosenson R.S. Current overview of statin-induced myopathy. Am J Med 116 (2004) 408
11. Akoglu H., Yilmaz R., Kirkpantur A., et al. Combined organ failure with combination antihyperlipidemic treatment: a case of hepatic injury and acute renal failure. Ann Pharmacother 41 (2007) 143
12. Goldstein J.L., and Brown M.S. Regulation of the mevalonate pathway. Nature 343 (1990) 425
13. Holstein S.A., Wohlford-Lenane C.L., and Hohl R.J. Consequences of mevalonate depletion. Differential transcriptional, translational, and post-translational up-regulation of Ras, Rap1a, RhoA, and RhoB. J Biol Chem 277 (2002) 10678
14. Leonard S., Beck L., and Sinensky M. Inhibition of isoprenoid biosynthesis and the post-translational modification of pro-p21. J Biol Chem 265 (1990) 5157
15. Dirks A.J., and Jones K.M. Statin-induced apoptosis and skeletal myopathy. Am J Physiol Cell Physiol 291 (2006) C1208
16. Macaluso M., Russo G., Cinti C., et al. Ras family genes: an interesting link between cell cycle and cancer. J Cell Physiol 192 (2002) 125
17. Olsson A.G. Expanding options with a wider range of rosuvastatin doses. Clin Ther 28 (2006) 1747
18. Baker S.K., and Tarnopolsky M.A. Statin myopathies: pathophysiologic and clinical perspectives. Clin Invest Med 24 (2001) 258
19. Bliznakov E.G. Lipid-lowering drugs (statins), cholesterol, and coenzyme Q10. The Baycol case a modern Pandora's box. Biomed Pharmacother 56 (2002) 56
20. Laaksonen R., Jokelainen K., Laakso J., et al. The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle. Am J Cardiol 77 (1996) 851
21. Lamperti C., Naini A.B., Lucchini V., et al. Muscle coenzyme Q10 level in statin-related myopathy. Arch Neurol 62 (2005) 1709
22. Paiva H., Thelen K.M., Van Coster R., et al. High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial. Clin Pharmacol Ther 78 (2005) 60
23. Koumis T., Nathan J.P., Rosenberg J.M., et al. Strategies for the prevention and treatment of statin-induced myopathy: is there a role for ubiquinone supplementation?. Am J Health Syst Pharm 61 (2004) 515
24. Langsjoen P.H., Langsjoen J.O., Langsjoen A.M., et al. Treatment of statin adverse effects with supplemental coenzyme Q10 and statin drug discontinuation. Biofactors 25 (2005) 147
25. Thompson P.D., Clarkson P.M., Rosenson R.S., et al. An assessment of statin safety by muscle experts. Am J Cardiol 97 (2006) 17
26. Alsheikh-Ali A.A., and Karas R.H. Safety of lovastatin/extended release niacin compared with lovastatin alone, atorvastatin alone, pravastatin alone, and simvastatin alone (from the United States Food and Drug Administration Adverse Event Reporting System). Am J Cardiol 99 (2007) 379
27. Talbert R.L. Safety issues with statin therapy. J Am Pharm Assoc 46 (2006) 479
28. Tokinaga K., Oeda T., Suzuki Y., et al. HMG-CoA reductase inhibitors (statins) might cause high elevations of creatine phosphokinase (CK) in patients with unnoticed hypothyroidism. Endocr J 53 (2006) 401
29. Evans M., and Rees A. The myotoxicity of statins. Curr Opin Lipidol 13 (2002) 415
30. Neuvonen P.J., Niemi M., and Backman J.T. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 80 (2006) 565
31. Ando H., Tsuruoka S., Yanagihara H., et al. Effects of grapefruit juice on the pharmacokinetics of pitavastatin and atorvastatin. Br J Clin Pharmacol 60 (2005) 494
32. Kantola T., Kivisto K.T., and Neuvonen P.J. Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. [see comment]. Clin Pharmacol Ther 63 (1998) 397
33. Lilja J.J., Neuvonen M., and Neuvonen P.J. Effects of regular consumption of grapefruit juice on the pharmacokinetics of simvastatin. Br J Clin Pharmacol 58 (2004) 56
34. Dreier J.P., and Endres M. Statin-associated rhabdomyolysis triggered by grapefruit consumption. Neurology 62 (2004) 670
35. Owczarek J., Jasinska M., and Orszulak-Michalak D. Drug-induced myopathies. An overview of the possible mechanisms. Pharmacol Rep 57 (2005) 23
36. Prueksaritanont T., Tang C., Qiu Y., et al. Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab Dispos 30 (2002) 1280
37. Hansen K.E., Hildebrand J.P., Ferguson E.E., et al. Outcomes in 45 patients with statin-associated myopathy. [see comment]. Arch Intern Med 165 (2005) 2671
38. Phillips P.S., Haas R.H., Bannykh S., et al. Statin-associated myopathy with normal creatine kinase levels. [see comment]. Ann Intern Med 137 (2002) 581
39. Troseid M., Henriksen O.A., and Lindal S. Statin-associated myopathy with normal creatine kinase levels. Case report from a Norwegian family. Apmis 113 (2005) 635
40. Sinzinger H., Wolfram R., and Peskar B.A. Muscular side effects of statins. J Cardiovasc Pharmacol 40 (2002) 163
41. Strommen J.A., Johns J.S., Kim C.T., et al. Neuromuscular rehabilitation and electrodiagnosis. 3. Diseases of muscles and neuromuscular junction. Arch Phys Med Rehabil 86 (2005) S18
42. * Trial). Am J Cardiol 92 (2003) 152
43. Smith C.C., Bernstein L.I., Davis R.B., et al. Screening for statin-related toxicity: the yield of transaminase and creatine kinase measurements in a primary care setting. [see comment]. Arch Intern Med 163 (2003) 688
44. Thompson P.D., Zmuda J.M., Domalik L.J., et al. Lovastatin increases exercise-induced skeletal muscle injury. Metabolism 46 (1997) 1206
45. Chong P.H., Boskovich A., Stevkovic N., et al. Statin-associated peripheral neuropathy: review of the literature. Pharmacotherapy 24 (2004) 1194
46. de Langen J.J., and van Puijenbroek E.P. HMG-CoA-reductase inhibitors and neuropathy: reports to the Netherlands Pharmacovigilance Centre. N J Med 64 (2006) 334
47. Gaist D., Jeppesen U., Andersen M., et al. Statins and risk of polyneuropathy: a case-control study. [see comment]. Neurology 58 (2002) 1333
48. Leis A.A., Stokic D.S., and Olivier J. Statins and polyneuropathy: setting the record straight. Muscle Nerve 32 (2005) 428